Build the capital's medical and health industry "nuclear explosion"

Zhongguancun Life Science Park, established in 2000, is a high-tech professional park with R&D and innovation in the fields of life science research, biotechnology and biomedicine as its main direction. It aims to develop the capital's knowledge economy and adjust Beijing's industrial structure by implementing the spirit of The State Council's "Reply on Accelerating the Construction of Zhongguancun Science and Technology Park". Major measures to enhance the capability of independent innovation.

In October 2006, the National Development and Reform Commission approved Zhongguancun Life Science Park as a "National biological industry Base". In 2021, the pharmaceutical and health enterprises in the park achieved revenue of 24.06 billion yuan, an increase of 27.2% year-on-year, driving the pharmaceutical and health industry revenue of Changping District to 71.71 billion yuan, an increase of 22% year-on-year; Enterprises in the park invested 9.140 billion yuan in research and development funds, an increase of 69.36% over the same period last year, which accelerated the development of the pharmaceutical and health industry.

Valley of Life Innovation Corridor

Zhongguancun Life Science Park is located in the west district of Future Science City, located in the Science and innovation corridor connecting Haidian District and Changping District "Golden Cross" Beiqing Road, which is an important support carrier for Beijing to build an international science and technology innovation center and build a world-leading science and technology park. At present, the park has three policy advantages of national functional zones: first, it has become an important part of Zhongguancun National Independent Innovation Demonstration Zone in the early stage of construction; Second, it will be included in the national comprehensive demonstration zone for expanding the opening up of the service industry in 2020; Third, the Life Science Park and its surrounding 10.26 square kilometers are included in the Science and Technology Innovation Area of the China (Beijing) Pilot Free Trade Zone, forming the development advantage of the superimposed policies of the three national functional areas.

The park has gathered more than 600 innovative pharmaceutical enterprises, more than 300 high-end talents, including 21 academicians, 4 Changjiang Scholars, 56 recipients of special government subsidies of The State Council, etc., 7 academician workstations, 21 postdoctoral research workstations, 10 national engineering research centers and key laboratories, 16 provincial and ministerial research and development centers. In terms of basic research, it has landed in a number of internationally renowned scientific research institutions such as Beijing Institute of Life Sciences, Beijing Brain Science and Brain Research Center, National Protein Science Center, and Beijing National Engineering Center for Biochips. In terms of research and development pilot test, Baonuo Technology and Kanglonghua have become representatives of clinical trial (CRO) enterprises to provide integrated drug research and development and pilot production services for biopharmaceutical projects, and gathered well-known innovative pharmaceutical companies such as Novo Nordisk, Beigene, Nuocheng Jianhua and Vitellon. In terms of production and circulation, it has attracted important pharmaceutical and medical device production and circulation enterprises such as New Era Health Group, Yangzijiang Pharmaceutical and Wantai Biology. In terms of clinical application, more than 3,000 beds of medical resources such as Peking University International Hospital, Peking University Sixth Hospital and Changbo International Research Hospital have been laid out, providing rich clinical resources for innovative medicine and medical device research and development of enterprises entering the park.

Build a comprehensive innovation service system

Zhongguancun Life Science Park has built a series of innovation and entrepreneurship service platforms, done a good job of incubation and transformation services for scientific research projects, introduced innovation incubation platforms such as New Nest Innovation Center and Darts International Innovation Platform, improved the professional operation service level, and fostered the rapid development of start-ups. Regularly hold activities such as innovation and entrepreneurship competition in the field of biological medicine, Science Asia Academic Forum, quality project recommendation meeting, etc., build an industrial exchange and exhibition platform, enhance the cooperation atmosphere of enterprises in the park, and further help scientists to link resources; Build a technology financial service platform, organize all kinds of venture capital represented by Life Park Financial supermarket, Life Park Innovation Investment fund and Life Park Industrial Development Fund, and provide enterprises with all-round financing services; Zhongguancun Lvtong North Platform, the only customs bonded warehouse located in the park, has been built to provide special approval, quarantine clearance, bonded logistics and other services for enterprises in the park, greatly shortening the customs clearance time of biological materials import and export for enterprises in the park.

The park has also cooperated with a number of enterprises and institutions to build a public platform, and cooperated with Huahui Anjian (Beijing) Biotechnology Co., LTD., to jointly build an intelligent GMP pilot platform for antibody drugs to help startups save research and development costs and shorten the research and development cycle. Cooperate with the Cell and Gene Therapy Innovation Center (CGTIC) of Tsinghua Institute of Technology to build a platform for cell and gene therapy research and development and pilot test, provide a complete industrial chain of cell and gene therapy drug research and development from preclinical research, pilot test to production, and accelerate the research and development process by combining artificial intelligence, 5G, automation and other technologies.

Build a global innovation network

Zhongguancun Life Science Park has gathered a group of high-level research and development institutions, gathered a group of top scientists and hundreds of high-level talents, and initially formed the whole industrial chain gathering trend of basic research, pilot research and development, production and circulation, and terminal medical treatment.

In the field of new drug research and development, a number of key enterprises such as Beigene, Novo Nordisk and Novo Nordisk have been brought together. In the field of innovative medical devices, a number of well-known enterprises such as Boao Bio, Wantai Bio and Mindray Medical, which are owned by Academician Cheng Jing, have settled in. The frontier field of gene and cell therapy has brought together a number of start-up biotechnology companies with explosive potential, such as Hopson Gene, Boya Jiyin, Huaxia Yingtai, etc. The field of precision medicine has brought together a large number of innovative enterprises with original and important achievements in molecular diagnostic gene sequencing, such as Novo Zhiyuan, Berry Hekang, and Panson.

The park has also gathered a number of service-oriented enterprises that do R&D outsourcing and production tool outsourcing for scientists, such as CRO enterprises such as Baonuo Technology, Pharmaron, and Junke Huasan. The second phase of Zhongguancun Life Science Park also gathers Peking University International Hospital (comprehensive Grade III), Peking University Sixth Hospital, Peking University Rehabilitation Hospital, and Hope Thyroid Hospital.

After more than 20 years of cultivation and development, the innovation achievements of Zhongguancun Life Science Park continue to emerge, and a large number of original new drugs have been launched and entered the world. In 2020, Zebutinib independently developed by Beigene and Obutinib independently developed by Notech Health were officially approved for listing, and these two first-class innovative drugs were sold in the United States.